This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Given the modest clinical benefits observed with immune checkpoint blockade in advanced prostate cancer, there is a renewed interest in exploring other forms of immunotherapy. Here, the authors report the use of a novel plasmid DNA vaccine encoding the androgen receptor, called pTVG-AR, in men with metastatic hormone-sensitive prostate cancer.
See related article by Kyriakopoulos et al., p. 5162
Footnotes
Clin Cancer Res 2020;26:5056–8
- Received June 30, 2020.
- Revision received July 14, 2020.
- Accepted July 29, 2020.
- Published first July 31, 2020.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
October 2020
Volume 26, Issue 19
Volume 26, Issue 19
Reimagining Vaccines for Prostate Cancer: Back to the Future
Jump to section
Advertisement